iBio, Inc.: reports preclinical IBIO-610 obese NHP data

What happened

• On Oct 13, 2026, iBio, Inc. issued a press release highlighting preclinical body-composition data from an eight-week obese non-human primate study evaluating IBIO-610, described as a potentially first-in-class Activin E antibody candidate. The data were discussed in an oral presentation at the European Association for the Study of Diabetes Annual Meeting on Oct 1, 2026.
• The filing states that the company plans to begin first-in-human studies in the first half of 2027.

Key details

• Study design: eight-week obese non-human primate study, n=6 per group.
• Body-composition results: lean mass accounted for 6% of weight loss with IBIO-610 plus semaglutide versus 22% with semaglutide alone; at week 8 fat accounted for 93% of weight lost with a single dose of IBIO-610 plus twice-weekly semaglutide versus 77% with semaglutide alone.
• Pharmacology: IBIO-610 produced a 97% reduction in serum levels of active Activin E at week 8 after a single intravenous dose.
• Pharmacokinetics: IBIO-610 had a 33.2-day half-life in NHPs, with a projected human half-life that the filing says could potentially support twice-yearly dosing.

Why it may matter

• Item 7.01 (Regulation FD disclosure) and Item 8.01 (other events) were reported; these items in the filing cover the company press release and disclosure of preclinical study data and the related presentation. This filing does not show why the insider traded or why the company acted.